<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03370601</url>
  </required_header>
  <id_info>
    <org_study_id>2015_23</org_study_id>
    <secondary_id>2015-A00940-49</secondary_id>
    <nct_id>NCT03370601</nct_id>
  </id_info>
  <brief_title>Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases</brief_title>
  <acronym>STAMP</acronym>
  <official_title>Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies (Increasing the Infliximab Dose or Introduction of Immunosuppressive Therapy) in Patients Chronic Inflammatory Bowel Diseases in Loss of Response to Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates 2 therapeutic strategies (increase infliximab dose or add an
      immunosuppressant) in patients with inflammatory bowel disease in loss of response to
      infliximab. Addition of an immunosuppressant may be more efficient at long term and is less
      expensive.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in Clinical remission</measure>
    <time_frame>At Week 52</time_frame>
    <description>the clinical remission is defined by Harvey Bradshaw (HBI) Index &lt; 4 for Crohn's disease or Simple Clinical Colitis Activity Index (SCCAI)&lt;4 for ulcerative colitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in deep remission</measure>
    <time_frame>At Week 52</time_frame>
    <description>clinical remission associated with endoscopic remission (CDEIS &lt;3 for CD patients or Mayo score&lt;2 for UC patients)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient in remission and clinical response</measure>
    <time_frame>At week 16</time_frame>
    <description>clinical response is defined as a decrease of at least 3 points of HBI for CD patients or SCCAI for UC patients compared to baseline (week 0).
Simple Clinical Colitis Activity Index (SCCAI)&lt;4 for ulcerative colitisHBI pour MC et SCCAI pour RCH &lt;4 associated at CRP &lt; 5 mg/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infliximab blood concentration</measure>
    <time_frame>Baseline, week 16 ad week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infliximab antibodies concentration</measure>
    <time_frame>Baseline, week 16 ad week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>economic criteria</measure>
    <time_frame>At week 52</time_frame>
    <description>medical fees in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patient with adverse effects and allergic reactions with infliximab</measure>
    <time_frame>At week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease questionnaire (score IBDQ)</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Optimisation strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Addition strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 10mg/kg every 8 weeks</description>
    <arm_group_label>Optimisation strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>6-mercaptopurine 1 à 1,5 mg/kg</description>
    <arm_group_label>Addition strategy</arm_group_label>
    <other_name>addition strategy with 6-mercaptopurine in second intention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Azathioprine 2 à 2.5mg/kg/j</description>
    <arm_group_label>Addition strategy</arm_group_label>
    <other_name>addition strategy with azathioprine in first intention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 5mg/kg every 8 weeks</description>
    <arm_group_label>Addition strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with ulcerative colitis or crohn's disease

          -  treated with infliximab (5mg/kg per 8 weeks) and with loss of response after at least
             4 infusions of infliximab

          -  active disease ( HBI &gt; 5 for CD patients or SCCAI&gt; 6 for UC patients)

          -  patients treated with infliximab only at the time of loss of response

        Exclusion Criteria:

          -  Patients with CD with ano perineal lesions and without luminal activity

          -  patients treated with cortico steroids and having had history of intolerance to
             azathioprin, 6-mercaptopurine or methotrexate

          -  patients with acute severe flare (HBI&gt;12 for CD patients and Lichtiger score &gt; 10 for
             UC patients)

          -  pregnant female

          -  patients with anal disease alone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Pariente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Pariente, MD</last_name>
    <phone>+ 33 3 20 44 53 21</phone>
    <email>benjamin.pariente@chru-lille.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Nachury, MD</last_name>
    <phone>+ 33 20 44 47 14</phone>
    <email>maria.nachury@chru-lille.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Pariente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crohn's disease</keyword>
  <keyword>ulcerative colitis</keyword>
  <keyword>infliximab</keyword>
  <keyword>loss of response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

